Clare S, Hartmann F A, Jooss M, Bachar E, Wong Y Y, Trepanier L A, Viviano K R
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI.
J Vet Intern Med. 2014 May-Jun;28(3):818-26. doi: 10.1111/jvim.12324. Epub 2014 Mar 27.
Long-duration beta-lactam antibiotics are used for empirical treatment in female dogs with uncomplicated bacterial cystitis. However, women with bacterial cystitis are treated with short-duration potentiated sulfonamides because longer courses of beta-lactams result in lower cure and higher recurrence rates.
HYPOTHESIS/OBJECTIVES: Short-duration potentiated sulfonamide treatment is more efficacious than long-duration beta-lactam treatment in achieving clinical and microbiological cures in female dogs with uncomplicated bacterial cystitis.
Thirty-eight client-owned female dogs.
Randomized, double-blinded, placebo-controlled clinical trial. Dogs were treated with TMP-SMX (15 mg/kg PO q12h for 3 days followed by a placebo capsule PO q12h for 7 days; Group SDS; n = 20) or cephalexin (20 mg/kg PO q12h for 10 days; Group LDBL; n = 18). Dogs were monitored for clinical and microbiological cure during treatment and at short- and long-term follow-up.
No statistically significant differences were found between treatment groups in clinical cure rates after 3 days of treatment (89% SDS, 94% LDBL; P = 1.00) and 4 days (85% SDS, 72% LDBL; P = .44) or >30 days (50% SDS, 65% LDBL; P = .50) after conclusion of treatment or in microbiological cure rates 4 days (59% SDS, 36% LDBL; P = .44) or >30 days (44% SDS, 20% LDBL; P = .40) after conclusion of treatment.
We did not identify a difference in cure rates between short-duration sulfonamide and long-duration beta-lactam treatments in female dogs with uncomplicated cystitis. Long-term cure rates in both treatment groups were low. In some female dogs, "uncomplicated" bacterial cystitis may be more complicated than previously recognized.
长效β-内酰胺类抗生素用于经验性治疗无并发症的雌性犬细菌性膀胱炎。然而,患有细菌性膀胱炎的女性使用短效增效磺胺类药物进行治疗,因为较长疗程的β-内酰胺类药物会导致治愈率降低和复发率升高。
假设/目标:在实现无并发症的雌性犬细菌性膀胱炎的临床和微生物学治愈方面,短效增效磺胺类药物治疗比长效β-内酰胺类药物治疗更有效。
38只客户拥有的雌性犬。
随机、双盲、安慰剂对照临床试验。犬只接受复方新诺明治疗(15mg/kg口服,每12小时一次,持续3天,随后每12小时口服一粒安慰剂胶囊,持续7天;SDS组;n = 20)或头孢氨苄治疗(20mg/kg口服,每12小时一次,持续10天;LDBL组;n = 18)。在治疗期间以及短期和长期随访中监测犬只的临床和微生物学治愈情况。
治疗3天后(SDS组89%,LDBL组94%;P = 1.00)、4天后(SDS组85%,LDBL组72%;P = 0.44)或治疗结束后>30天(SDS组50%,LDBL组65%;P = 0.50),治疗组之间的临床治愈率无统计学显著差异;治疗结束后4天(SDS组59%,LDBL组36%;P = 0.44)或>30天(SDS组44%,LDBL组20%;P = 0.40),微生物学治愈率也无统计学显著差异。
我们未发现无并发症膀胱炎的雌性犬中,短效磺胺类药物和长效β-内酰胺类药物治疗在治愈率上存在差异。两个治疗组的长期治愈率均较低。在一些雌性犬中,“无并发症”的细菌性膀胱炎可能比之前认为的更为复杂。